Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5478 - IL-8 as a Pharmacodynamic biomarker for TGF-β2 antisense (trabedersen) therapy – Results of a Phase II trial


11 Sep 2017


Poster display session


Clinical Research;  Cancers in Adolescents and Young Adults (AYA);  Translational Research


Larn Hwang


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


L. Hwang1, W. Wang1, S. Qazi2, K. Ng2, O. D’cruz2, V. Trieu1

Author affiliations

  • 1 Clinical Research, Oncotelic Inc, 91301 - Agoura Hills/US
  • 2 Clinical Research, Autotelic Inc., 92626 - Costa Mesa/US


Abstract 5478


In a Phase I/II study of Trabedersen (OT-101), a phosphorothioate antisense specific for human TGF- β2 mRNA, patients with advanced pancreatic cancer (PAC) treated in the 2nd-line and beyond exhibited improved overall survival (OS) when OT-101 was followed with chemotherapy. Here, we examined the association between plasma levels of cyto-/chemokines and OS outcomes to identify potential biomarkers for improved OS.


37 PAC patients were treated with continuous IV infusion in escalating doses of 2 treatment schedules (7-days-on, 7-days-off and 4-days-on, 10-days-off). Plasma levels of 31 cyto-/chemokines were measured at 8 separate time points over 3 cycles of OT-101 treatment (140 mg/m2/day, 4-days-on, 10-days-off). Standardized maximum levels of individual cyto-/chemokines on Day 2 were subtracted from levels on Day 5 of each cycle of treatment and correlated with log10 transformed OS values. Feedback interactions with PK parameters were also investigated utilizing an ANCOVA model.


A median OS of 14.5 months and 2.6 months was observed for 2nd-line patients treated with and without subsequent chemotherapies, respectively (p = 0.0009). Increasing difference of IL-8 levels at Day 2 vs Day 5 was positively correlated with OS (R2 = 0.58, P = 0.0066). Stratifying for patients with and without chemo, R2 increased to 0.99 and 0.77 respectively. Similar results were observed for IL-15, with R2 = 0.93 in patients with chemo and R2 = 0.50 in those without. ANCOVA models for two PK parameters exhibited significant model fits (F3,7 = 7.89, P = 0.012 for Simulated Vz Mean; F3,7 = 8.18, P = 0.011 for Simulated Cl Mean) and the interaction effects resulted in lower p-values for the correlation of OS vs IL-8 levels.


Increasing peak levels of IL-8 and IL-15 response on Day 2 of OT-101 treatment correlated with OS in PAC patients. This correlation with OS was evident regardless of subsequent chemotherapy or not indicating spikes in IL-8 and IL-15 as potential biomarkers for OT-101.

Clinical trial identification

Legal entity responsible for the study

Oncotelic Inc.


Oncotelic Inc.


L. Hwang, W. Wang, S. Qazi, K. Ng, O. D’cruz, V. Trieu: Employee

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.